Case report

[A Case of Pembrolizumab-Associated Fulminant Type One Diabetes Mellitus during Neoadjuvant Chemotherapy for Early-Stage Breast Cancer].

R. Amano H. Seki Kazuki Yasuda Shoko Yao Ai Tsuchiya K. Miyamoto Yoshiharu Ishizaka Kaishi Satomi Yoshika Wada S. Imoto

Sep 2026 · Gan to kagaku ryoho. Cancer & chemotherapy · Vol 53 9, pp. 587-591 · 0 citations

Medicine

TL;DR

Fulminant T1DM is a rare irAE with an incidence of < 0.1%.

PubMed Semantic Scholar

View source

Similar papers

Case report Open access Sep 2026

Combining Pembrolizumab and Ofatumumab in Triple-Negative Breast Cancer and Multiple Sclerosis: A Case Report

ABSTRACT INTRODUCTION Pembrolizumab has been widely used since its approval as perioperative therapy for triple-negative breast cancer. While the emergence of diverse antibody drugs has expanded therapeutic options in recent years, reports on the combined use of immune-related antibodies in patients with other diseases...

Haruna Iriyama, M. Iwase, Yuko Takano et al. · Surgery Case Reports · 0 citations

Case report Open access Sep 2026

[Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment.]

The case concerns a 68-year-old female patient with metastatic HR-positive/HER2-negative pleomorphic lobular breast carcinoma and severe chronic renal impairment since diagnosis, previously treated with multiple lines of therapy. At diagnosis in September 2021, the disease was already metastatic, with bone, nodal, and...

C. Martinelli · Recenti progressi in medicin... · 0 citations

Case report Open access Sep 2026

[Sacituzumab govitecan in ER+/HER2- breast cancer: a necessary treatment option for patients who have undergone multiple prior treatments.]

A 65-years-old woman underwent right mastectomy in 2010 for invasive ductal carcinoma of the breast (HR=95% PgR=18% ki67= 25% HER2= 0). Stage pT2(30mm)pN1(2/10)M0. She started adjuvant chemotherapy then endocrine therapy. In March 2021 a CT scan showed suspected right breast and axillary lymph node recurrence; a biopsy...

L. Scortichini, N. Battelli · Recenti progressi in medicin... · 0 citations

Open access Sep 2026

Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study

In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.

B. Sharaf, T. Al-Batsh, Suhaib Khater et al. · Breast Cancer · 0 citations

Review Open access Oct 2026

Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review

As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced fulminant type 1 diabetes mellitus (FT1DM) remain rare. This article repor...

Shu-Jun Sun, Liang Su, Xiao-Jing Ma et al. · Frontiers in Endocrinology · 0 citations

Sep 2026

Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?

Gains in event-free and overall survival from the KEYNOTE-522 trial have incorporated pembrolizumab into the neoadjuvant and adjuvant armamentarium for stage II-III triple-negative breast cancer (TNBC). However, the lack of a second randomization to pembrolizumab after surgery raises the question of whether the adjuvan...

V. Liutti, H. Wildiers, G. Sonke et al. · European Journal of Cancer · 0 citations